S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL by Aleksandra Urban, Johanne Hermansen, Yanping Yin, Weikaixin Kong, Rebecca Teglgaard, Christian Brieghel, Sabina Kersting, Geir E. Tjønnfjord, Mark-David Levin, Hoa T. T. Tran, Mattias Mattsson, Juha Ranti, Gerrit-Jan Veldhuis, Caspar Da Cunha-Bang, Rogier Mous, Julie Dubois, Arnon Kater, Carsten Niemann, Tero Aittokallio, Sigrid Skånland

Get full text